Evidence map›Paper›PMID 39136444›Full record

ArticleBiomarkers in medicine2024

α-1 antitrypsin is promising for the identification of glaucoma severity and is associated with glaucomatous neural damage.

Hang Yuan, An Li, Lingling Chen, Zuo Wang, Xiong Zhu, Jinxia Wang, Wenbo Xiu, Yang Chen, Gao Zhang, Donghua Liu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarkers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hang YuanDepartment of Immunology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, 610041, China.
An LiClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science & Technology of China, Chengdu, 611731, China.
Lingling ChenDepartment of Immunology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, 610041, China.
Zuo WangClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science & Technology of China, Chengdu, 611731, China.
Xiong ZhuDepartment of Prenatal Diagnosis, Chengdu Women's & Children's Central Hospital, School of Medicine, University of Electronic Science & Technology of China, Chengdu, 610015, China.
Jinxia WangClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science & Technology of China, Chengdu, 611731, China.
Wenbo XiuClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science & Technology of China, Chengdu, 611731, China.
Yang ChenClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science & Technology of China, Chengdu, 611731, China.
Gao ZhangClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science & Technology of China, Chengdu, 611731, China.
Donghua LiuClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science & Technology of China, Chengdu, 611731, China.
Xiao XiaoClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science & Technology of China, Chengdu, 611731, China.
Chaonan SunClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science & Technology of China, Chengdu, 611731, China.
Fang LuClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science & Technology of China, Chengdu, 611731, China.ORCID 0000-0002-8927-2437
Lijuan HuDepartment of Immunology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, 610041, China.
Chong HeClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science & Technology of China, Chengdu, 611731, China.ORCID 0000-0002-0228-1833

Funding

Foundation of Sichuan Science and Technology Department 2022NSFSC1380National Natural Science Foundation of China U19A2004, 81970803, and 82370560Open Project of Sichuan Provincial Key Laboratory for Clinical Immunology Translational Medicine LCMYZHYX-KFKT202204
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

alpha 1-AntitrypsinBiomarkersGlaucomaSeverity of Illness IndexAgedCase-Control StudiesFemaleHumansMaleMiddle AgedROC Curvealpha 1-AntitrypsinBiomarkersdisease severityglaucomaprogressionα-1 antitrypsin

Identifiers

PMID39136444
PMCPMC11364068

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.